Monopar Therapeutics
在场
Monopar Therapeutics 是一家在股票代码 MNPR (US) 下上市的公司。
高管
查看带有其 7 名主要高管的组织结构图
Monopar Therapeutics 搜索最多的简介
- Chandler Robinson, Chief Executive Officer and Board Membe
- Michael Brown, Director
- Raymond Anderson, Director
高管在Monopar Therapeutics变化
- Karthik RadhakrishnanKarthik Radhakrishnan 将于20246月30作为 Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer 加入公司 (新闻发布的2024五月28号).
- Kim Tsuchimoto, Chief Financial Officer, Secretary and Treasurer, 将于 20246月29 退休 (新闻发布的2024五月26号).
创建提醒
跟踪 Monopar Therapeutics 的高管变动
生物技术
Monopar Therapeutics 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Monopar Therapeutics 的最新新闻稿
- Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
- Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
- Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
- Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
- Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
- Press Releases
- Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
- Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
- Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
- View more press releases Close
通过电子邮件
